Breaking News
October 16, 2018 - Study uncovers important role of PRMT1 in dilated cardiomyopathy
October 16, 2018 - Nutritional quality of breakfast linked to cardiovascular and metabolic risk factors in children
October 16, 2018 - Scientists develop dual anthrax-plague vaccine
October 16, 2018 - Poor Outcomes for Hispanic Infants With Congenital Heart Dz
October 16, 2018 - Global study finds youngest in class more likely to be diagnosed with ADHD
October 16, 2018 - Researchers sequence two selfish genes in the fungus Neurospora intermedia
October 16, 2018 - Survey results highlight the need for better communication between patients and HCPs about bacterial vaginosis
October 16, 2018 - Researchers develop fibrin-targeting immunotherapy to protect against neurodegeneration
October 16, 2018 - Researchers create open access database on healthy immunity
October 16, 2018 - Rice University chemist wins big award to study small surfaces
October 16, 2018 - Study finds 43% drop in stroke rate
October 16, 2018 - Researchers identify basic relationships of cell cycle and cellular senescence in the placenta
October 16, 2018 - Obesity Doubles Odds for Colon Cancer in Younger Women
October 16, 2018 - Adults with ADHD not constrained in creativity
October 16, 2018 - Raising visibility for people and students with chronic illness and disability
October 16, 2018 - Allele awarded NIH grant to develop nanoantibody therapies for treatment of sepsis
October 16, 2018 - Only 59% of young adults undergoing surgery are fluid responsive
October 16, 2018 - Research points to potential new treatment for hearing loss
October 16, 2018 - MDI Biological Laboratory receives $1.2 million SEPA grant to promote data literacy
October 16, 2018 - Vast majority of dementia cases may arise from spontaneous genetic errors
October 16, 2018 - New project aims to deliver fast, effective treatment for autoimmune rheumatic diseases
October 16, 2018 - Study identifies molecular switch that controls fate of milk-producing breast cells
October 16, 2018 - Research shows diet has little influence on precursor to gout
October 16, 2018 - “Without Dr. Shumway doing his miracle work, three generations would not be here”: A Stanford heart transplant patient’s story
October 16, 2018 - Non-invasive brain stimulation sheds light on neurobiology underlying implicit bias
October 16, 2018 - Researchers demonstrate integrated technique to control production of cell therapeutics
October 16, 2018 - Breast tomosynthesis detects 34% more tumors than traditional mammography
October 16, 2018 - Rhode Island Hospital, Brown receive $800,000 grant to keep up fight against opioid epidemic
October 16, 2018 - UVA partners with health systems in AVIA network’s Medicaid Transformation Project
October 16, 2018 - Trevena Announces Oliceridine FDA Advisory Committee Meeting Outcome
October 16, 2018 - Study reveals early warning signs of heart problems in patients with newly diagnosed lupus
October 16, 2018 - Connecting the dots of Alzheimer’s disease
October 16, 2018 - New publication offers evidence-based content for global breast imaging medical community
October 16, 2018 - ‘EinsteinVision’ that improves hand-eye coordination of surgeons introduced at Harefield Hospital
October 16, 2018 - WRAIR clinical study evaluates safety and immunogenicity of Marburg vaccine
October 16, 2018 - Ketamine can be considered as alternative to opioids for short-term pain control in ED
October 16, 2018 - Endurance exercise training beneficially alters gut microbiota composition
October 15, 2018 - FDA Approves Yutiq (fluocinolone acetonide intravitreal implant) for Chronic Non-Infectious Posterior Segment Uveitis
October 15, 2018 - Birthing Options for Full-Term Pregnancy
October 15, 2018 - Stressed, toxic, zombie cells seen for first time in Alzheimer’s
October 15, 2018 - Concussion researchers study head motion in high school football hits | News Center
October 15, 2018 - Neuropsychiatric symptoms related to earliest stages of Alzheimer’s brain pathology
October 15, 2018 - Neck collar device may help protect the brain of female high school soccer players
October 15, 2018 - Research reveals how the inner ear processes speech
October 15, 2018 - Many parents still skeptical about safety and effectiveness of flu shot, survey finds
October 15, 2018 - Payer Policies May Discourage Non-Pharma Tx for Low Back Pain
October 15, 2018 - Exercise may delay cognitive decline in people with rare Alzheimer’s disease
October 15, 2018 - Researchers modify CRISPR to reorganize genome | News Center
October 15, 2018 - Innovative brain tumor operation set to tailor to patients’ needs
October 15, 2018 - Findings offer new insight into early changes that occur during AD pathology
October 15, 2018 - Neurons regulating reproductive hormone release have different activity in epileptic mice
October 15, 2018 - More parents are concerned about taking babies swimming in public pools
October 15, 2018 - Health Tip: Know the Risk Factors for Lower Back Pain
October 15, 2018 - Study shows cigarillo flavors enhanced by high-intensity sweeteners
October 15, 2018 - Study traces hospital-acquired bloodstream infections to patients’ own bodies | News Center
October 15, 2018 - Abnormal vision in childhood can affect development of brain areas responsible for attention
October 15, 2018 - Study highlights need for increased support for alcohol-related liver disease patients
October 15, 2018 - Color-changing contact lens could help doctors to monitor eye disease medications
October 15, 2018 - Tobacco heating products cause less staining to teeth than conventional cigarettes
October 15, 2018 - Young adults who are obese can expect to lose up to 10 years in life expectancy
October 15, 2018 - Scientists uncover how proteins meet on the cell membrane
October 15, 2018 - Affordable housing with supportive social services for senior citizens can reduce hospital use
October 15, 2018 - Schiller Easy Pulse Saves Lives
October 15, 2018 - The latest ECG device from Schiller
October 15, 2018 - Following a Tissue Sample
October 15, 2018 - Prisoners need drug and alcohol treatments but AA programs aren’t the answer
October 15, 2018 - Andrea Califano and Jordan Orange Elected to National Academy of Medicine
October 15, 2018 - The impending risk of African Swine Fever Virus
October 15, 2018 - Breastfeeding reduces the number of antibiotic-resistant bacteria in infant gut
October 15, 2018 - Researchers develop comprehensive molecular atlas of postnatal mouse heart development
October 15, 2018 - ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting
October 15, 2018 - Engineering teratoma-derived fibroblasts to enhance osteogenesis
October 15, 2018 - Lab study shows effectiveness of potential therapy for treatment-resistant hypothyroidism
October 15, 2018 - JCU study firms up association between diet and depression
October 15, 2018 - Researchers to study the use of CRISPR on human liver on-a-chip platform
October 15, 2018 - Sub-concussive impacts not associated with decline in neurocognitive function
October 15, 2018 - Researchers find potential treatment to halt premature labor and birth
October 15, 2018 - As U.S. suicides rates rise, Hispanics show relative immunity
October 15, 2018 - FDA Issues a Complete Response Letter to Acacia Pharma for Barhemsys
October 15, 2018 - Photoactive bacteria bait may help in fight against MRSA infections
New SERM Shows Promise in Advanced Breast Cancer

New SERM Shows Promise in Advanced Breast Cancer

image_pdfDownload PDFimage_print

Action Points

  • In women with estrogen receptor-positive, hormone-refractory metastatic breast cancer, oral Z-endoxifen hydrochloride, the potent metabolite of tamoxifen, provided substantial drug exposure regardless of CYP2D6 genotype, acceptable toxicity, and promising antitumor activity.
  • Note that the study was unable to determine the maximum-tolerated dose of oral endoxifen, and dose escalation was discontinued at 160 mg per day and endoxifen concentrations >1,900 ng/mL.

In women with estrogen receptor-positive, hormone-refractory metastatic breast cancer, oral Z-endoxifen hydrochloride, the potent metabolite of tamoxifen, provided substantial drug exposure regardless of CYP2D6 genotype, acceptable toxicity, and promising antitumor activity, researchers reported.

Results from a phase I study in 38 patients with metastatic breast cancer demonstrated a clinical benefit rate (stable disease ≥ 6 months) of 26.3%. including a partial response by RECIST criteria in three patients who experienced progression during prior tamoxifen therapy, according to Matthew P. Goetz, MD, of the Mayo Clinic in Rochester, Minnesota, and colleagues.

Clinical benefit was also seen in seven patients who had no prior tamoxifen treatment or who didn’t experience progression with adjuvant tamoxifen. The median progression-free survival (PFS) time was 110 days, with a 1-year PFS rate of 15%, they wrote online in the Journal of Clinical Oncology.

The study was unable to determine the maximum-tolerated dose of oral endoxifen, and dose escalation was discontinued at 160 mg per day and endoxifen concentrations >1,900 ng/mL. At the time of data lock on March 5, 2017, seven patients had died due to metastatic breast cancer. Of the 31 patients who were alive, two did not have disease progression and 29 did.

Notably, CYP2D6 — the enzyme that converts tamoxifen to endoxifen — was not associated with either Z-endoxifen oral clearance or PFS, the study showed.

Based on these results, “The relationship between CYP2D6 genotype, endoxifen exposure, and the antitumor benefit of both drugs will be evaluated in the randomized phase II trial of Z-endoxifen and tamoxifen,” authors wrote. The trial will directly compare endoxifen (80 mg/day) with tamoxifen (20 mg/day) in women with prior aromatase inhibitor (AI) progression.

For the current study, 41 women were enrolled from March 25, 2011 to Dec. 9, 2014, and 38 were included in the maximum-tolerated dose (MTD) determination. A total of 36 patients experienced progression while on an AI, 21 while on fulvestrant (Faslodex), and 15 progressed on prior tamoxifen therapy.

Patients received 20, 40, 60, 80, 100, 120, or 160 mg of Z-endoxifen by mouth daily or until unable to continue treatment. Dose levels 40, 80, and 100 mg/day were also studied in the expansion phase of the trial. Of the 16 patients enrolled in the expansion cohorts, six were randomized to 40 mg/day, five to 80 mg/day, and five to 100 mg/day.

Dose-limiting toxicities were reported in two patients at the 60-mg dose: a pulmonary embolus after one cycle of treatment and a grade 4 hypertriglyceridemia after five treatment cycles. No eye toxicity was observed and there were no adverse effects reported in the expansion cohorts.

“Long-term studies will be necessary to fully evaluate the adverse effect profile of Z-endoxifen,” the authors said.

Other selective ER modulators (SERMs) have been shown to reduce cholesterol levels and endoxifen appears to do the same. Preliminary results suggest this new SERM reduces both total and LDL cholesterol levels.

Patients with low CYP2D6 enzyme activity exhibit significantly lower endoxifen concentrations when treated with tamoxifen, Goetz’s group pointed out. Data from this study indicate that even non-therapeutic levels of Z-endoxifen can have antitumor activity in patients experiencing progression with tamoxifen, they said.

Patients with prior tamoxifen exposure and a CYP2D6 activity score ≥2.0 generally had rapid clinical progression with a shorter median PFS compared with patients with reduced CYP2D6 metabolism and an activity score ≤1.5 (61 vs 132 days, respectively, P=0.046).

In an accompanying editorial, V. Craig Jordan, PhD, of the MD Anderson Cancer Center in Houston, said that while the value of endoxifen as a salvage therapy will be determined in future clinical studies, “this could just be the beginning of a new era. Perhaps it is the right time to consider improving women’s health with a new SERM.”

More than 30 years ago, Jordan — known as the “Father of Tamoxifen” — discovered that the drug’s anti-estrogenic properties could halt breast cancer growth, thus paving the way for SERMs.

Although AIs are the current standard of care in postmenopausal women with breast cancer, the consequences of long-term therapy remain a concern, he noted.

“Improvements in the use of SERMs may be an important first step in creating an improved quality of life for an aging population,” suggested Jordan, noting that using adjuvant tamoxifen therapy for 10 years makes it possible “to save the lives of 50% of patients with ER-positive breast cancer.”

In addition to potentially reducing risk of breast cancer recurrence, a new SERM might also improve overall health in menopausal women by lowering risk of osteoporosis, coronary heart disease, and stroke without increasing the odds of endometrial cancer, Jordan pointed out.

“It is not just about being alive; it is about being well,” he wrote.

The study was funded by the Mayo Clinic, the Regis Foundation, Prospect Creek Foundation, the George M. Eisenberg Foundation for Chanties, and the National Cancer Institute.

Goetz disclosed relevant relationships with Eli Lilly, bioTheranostics, RNA Diagnostics, Eli Lilly, and Pfizer. Co-authors disclosed multiple relevant relationships with industry.

Jordan disclosed no relevant relationships with industry.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2017-10-31T09:30:00-0400

Tagged with:

About author

Related Articles